Gamco Investors INC. ET AL Sells 355 Shares of Illumina, Inc. (NASDAQ:ILMN)

Gamco Investors INC. ET AL lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 18.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,585 shares of the life sciences company’s stock after selling 355 shares during the period. Gamco Investors INC. ET AL’s holdings in Illumina were worth $212,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. M&T Bank Corp grew its holdings in Illumina by 3.4% during the 3rd quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company’s stock worth $7,091,000 after acquiring an additional 1,769 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Illumina during the third quarter worth $772,000. Tidal Investments LLC grew its stake in shares of Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock worth $580,000 after purchasing an additional 1,226 shares during the period. B. Riley Wealth Advisors Inc. increased its holdings in Illumina by 66.8% in the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock valued at $1,582,000 after purchasing an additional 4,797 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ILMN. Barclays cut their price target on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a research report on Thursday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Guggenheim reduced their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Piper Sandler increased their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $138.70.

Illumina Stock Down 3.2 %

ILMN stock opened at $71.21 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company has a market cap of $11.27 billion, a price-to-earnings ratio of -9.27, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $84.61 and a two-hundred day moving average price of $120.27.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.